Business ❯ Pharmaceutical Industry ❯ Market Competition

Drug Pricing

Novo Nordisk Generic Medications Eli Lilly Consumer Health Weight Loss Solutions Compounded Drugs Access to Medication Novo Nordisk's Semaglutide Emerging Therapies Patent Issues

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

The once-daily peptide offers biologic-like efficacy without injections.

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

Canada Opens Path to Generic Ozempic as Health Canada Weighs Nine Applications

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA OKs RVO Use and Monthly Dosing for Regeneron’s Eylea HD

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

FDA Approves Keytruda QLEX, a Rapid Subcutaneous Option for Most Adult Solid Tumor Uses

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

Eli Lilly Expands Legal Fight Against Compounded GLP-1 Drugs

Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

Amgen Advances Weight-Loss Drug MariTide with Two Phase 3 Trials

Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

Summit Therapeutics' Lung Cancer Drug Outperforms Merck's Keytruda in Trial